Nelson Roberts Investment Advisors LLC continued to hold its position in Bristol-Myers Squibb Company (NYSE:BMY) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,400 shares of the biopharmaceutical company’s stock at the end of the first quarter. Nelson Roberts Investment Advisors LLC’s holdings in Bristol-Myers Squibb were worth $131,000 at the end of the most recent quarter.
A number of other institutional investors also recently bought and sold shares of BMY. Union Bankshares Corp increased its position in Bristol-Myers Squibb by 12.2% in the first quarter. Union Bankshares Corp now owns 4,405 shares of the biopharmaceutical company’s stock valued at $240,000 after buying an additional 480 shares in the last quarter. Norges Bank acquired a new position in Bristol-Myers Squibb during the fourth quarter valued at $770,318,000. Doyle Wealth Management acquired a new position in Bristol-Myers Squibb during the first quarter valued at $14,571,000. Philadelphia Trust Co. increased its position in shares of Bristol-Myers Squibb by 7.7% in the fourth quarter. Philadelphia Trust Co. now owns 20,924 shares of the biopharmaceutical company’s stock worth $1,223,000 after buying an additional 1,500 shares during the period. Finally, Numeric Investors LLC purchased a new position in shares of Bristol-Myers Squibb during the fourth quarter worth approximately $1,671,000. 69.68% of the stock is currently owned by institutional investors and hedge funds.
Shares of Bristol-Myers Squibb Company (NYSE:BMY) traded down 0.62% during trading on Friday, reaching $56.42. 4,809,885 shares of the company’s stock traded hands. The company has a 50 day moving average of $55.95 and a 200-day moving average of $54.96. The company has a market capitalization of $92.52 billion, a price-to-earnings ratio of 20.61 and a beta of 1.17. Bristol-Myers Squibb Company has a 1-year low of $46.01 and a 1-year high of $60.45. Bristol-Myers Squibb also saw some unusual options trading on Thursday. Traders purchased 781 put options on the company. This represents an increase of 117% compared to the average volume of 360 put options.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.01. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The business had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.09 billion. During the same period in the previous year, the business earned $0.69 earnings per share. The company’s revenue was up 5.6% on a year-over-year basis. Equities analysts predict that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, August 1st. Investors of record on Friday, July 7th were paid a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.76%. The ex-dividend date was Wednesday, July 5th. Bristol-Myers Squibb’s dividend payout ratio is currently 56.73%.
ILLEGAL ACTIVITY WARNING: This news story was first posted by BNB Daily and is the property of of BNB Daily. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.baseball-news-blog.com/2017/08/19/bristol-myers-squibb-company-nysebmy-stake-maintained-by-nelson-roberts-investment-advisors-llc-updated-updated-updated.html.
A number of brokerages have commented on BMY. BidaskClub raised shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Saturday, August 12th. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a research report on Wednesday, August 9th. Vetr upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $64.08 price target for the company in a research report on Thursday. Cowen and Company set a $65.00 price target on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Monday, August 14th. Finally, Credit Suisse Group set a $58.00 price target on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Wednesday. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $62.12.
In related news, Director Theodore R. Samuels II acquired 6,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 2nd. The shares were acquired at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the completion of the purchase, the director now directly owns 18,000 shares in the company, valued at $1,006,920. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.23% of the stock is owned by insiders.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.